BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Responds to Letter from Pointillist Family Office

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement

Related news

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

HYPRHyperfine2026-08-26 12:15 EST

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

Stock data

Close
3.00 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States